Goldman Sachs analyst Asad Haider raised the firm’s price target on Johnson & Johnson to $250 from $240 and keeps a Buy rating on the shares. The setup is strong for another strong year with ongoing momentum in Innovative Medicine and MedTech, both of which demonstrated better-than-expected Q4 trends ahead of tailwinds in 2026 with multiple new product cycles continuing to unfold, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $221 from $220 at BofA
- Johnson & Johnson price target raised to $250 from $232 at Citi
- Johnson & Johnson price target raised to $240 from $230 at Wells Fargo
- Johnson & Johnson: Solid Fundamentals but Fully Valued with Litigation Overhang Supporting Hold Rating
- Johnson & Johnson Projects Strong Growth Beyond STELARA